Who are Ranibizumab plus Photodynamic therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ranibizumab-plus-photodynamic-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ranibizumab plus Photodynamic therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ranibizumab plus Photodynamic therapy (Ranibizumab plus Photodynamic therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy. Area: Ophthalmology.

marketed Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy VEGF-A (ranibizumab component) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Ranibizumab plus Photodynamic therapy (Ranibizumab plus Photodynamic therapy) — Illinois Retina Associates. Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ranibizumab plus Photodynamic therapy TARGET	Ranibizumab plus Photodynamic therapy	Illinois Retina Associates	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy class)

Illinois Retina Associates · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ranibizumab plus Photodynamic therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/ranibizumab-plus-photodynamic-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab